Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, including in the U.S.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The millennial-focused digital health company Hims & Hers (HIMS) has donated $1 million to President-elect Donald Trump’s ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.